Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
| Image |  |
|---|---|
| Description | scientific article published on 23 February 2010 |
| Author/s |
author: Camillo Porta |
| Publication date | February 23, 2010 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |